Key result
The molecular mechanism of Brugada syndrome remains elusive in 70-85% of cases, suggesting a complex interplay of rare and common genetic variants rather than a strictly Mendelian inheritance.
Why the study?
The molecular mechanism of Brugada syndrome remains elusive in 70-85% of cases, and the causative role of previously reported genes and the interplay between rare and common variants remain uncertain.
Answers are grounded in this paper and cite their sources.
Brugada syndrome is increasingly recognized as a potentially oligogenic or polygenic condition rather than a strict Mendelian disease, highlighting the need for polygenic risk scores and further genetic studies.
Brugada syndrome (BrS) is diagnosed by a coved-type ST-segment elevation in the right precordial leads on the electrocardiogram (ECG), and it is associated with an increased risk of sudden cardiac death (SCD) compared to the general population. Although BrS is considered a genetic disease, its molecular mechanism remains elusive in about 70–85% of clinically-confirmed cases. Variants occurring in at least 26 different genes have been previously considered causative, although the causative effect of all but the SCN5A gene has been recently challenged, due to the lack of systematic, evidence-based evaluations, such as a variant’s frequency among the general population, family segregation analyses, and functional studies. Also, variants within a particular gene can be associated with an array of different phenotypes, even within the same family, preventing a clear genotype–phenotype correlation. Moreover, an emerging concept is that a single mutation may not be enough to cause the BrS phenotype, due to the increasing number of common variants now thought to be clinically relevant. Thus, not only the complete list of genes causative of the BrS phenotype remains to be determined, but also the interplay between rare and common multiple variants. This is particularly true for some common polymorphisms whose roles have been recently re-evaluated by outstanding works, including considering for the first time ever a polygenic risk score derived from the heterozygous state for both common and rare variants. The more common a certain variant is, the less impact this variant might have on heart function. We are aware that further studies are warranted to validate a polygenic risk score, because there is no mutated gene that connects all, or even a majority, of BrS cases. For the same reason, it is currently impossible to create animal and cell line genetic models that represent all BrS cases, which would enable the expansion of studies of this syndrome. Thus, the best model at this point is the human patient population. Further studies should first aim to uncover genetic variants within individuals, as well as to collect family segregation data to identify potential genetic causes of BrS.
No takes yet. Share an insight, caveat, or question.
Monasky et al. (2020) conducted a review in Brugada syndrome. The molecular mechanism of Brugada syndrome remains elusive in 70-85% of cases, suggesting a complex interplay of rare and common genetic variants rather than a strictly Mendelian inheritance.
Synapse has enriched 10 related papers. Consider them for comparative context: